Association of Prostate-Specific Antigen Level and Prostate Cancer : Retrospective Cohort Study
Keywords:
prostate-specific antigen, prostate cancer, prostate cancer detection rateAbstract
Objective:This was to study the relationship between the prostate spacefic antigen level and prostate cancer detection rates across different PSA ranges.
Methods: The researcher reviewed the medical records of benign prostate hyperplasia patients who had been treated at Chaophraya Yommarat Hospital for the past 5 years since 1 January 2016-31 December 2020 with blood PSA levels greater than 4 nanogram/millilitre (ng/ml) and received pathological reports after prostate biopsies. The patients were divided into 3 groups according to PSA levels as follows : 4-9.9 ng/ml, 10-19.9 ng/ml, and over 20 ng/ml. This was to calculate prostate cancer detection rates in different PSA ranges.
Results: Total 413 patients, the mean age of the patients was 68.49 years (standard deviation 7.71), mean PSA values 53.24 ng/ml (standard deviation 159.57, minimum 4 ng/ml, maximum 1,648 ng/ml). The overall prostate cancer detection rate was 30.5%. The prostate cancer detection rate increased statistically with advancing age and higher PSA values. We found prostate cancer detection rates of 21.7%, 25.1%, and 39.8% in the age group 50-60 years, 61-70 years, and the age group over 70 years, respectively ( p < .01) ; prostate cancer detection rates of 11.7 percent, 21.2%, and 73.8 percent in PSA 4-9.9 ng/ml , 10-19.9 ng/ml , and PSA over 20 ng/ml, respectively (p < .01). Complications after prostate biopsies showed high fever with urinary tract infection 14 patients (3.3%), hematuria 5 patients (1.2 percent), and urinary retention 13 patients (3.2 percent) . There was no complication in 381 patients (92.3%).
Conclusion: The overall prostate cancer detection rate was 30.5%.Prostate cancer detection rates increase with advancing age by as high as a 39.8% in the age group over 70 years old ; and with higher PSA values especially, if the PSA was above 20 ng/ml there was a 73.8% detection rate for prostate cancer.
References
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239–46.
Virani S, Bilheem S, Chansaard W, et al. National and Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with the Highest Burdens. Cancers (Basel) 2017;9(8):108.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30.
Khazaei, S. Rezaeian, S. Ayubi, et al. Global prostate cancer incidence and mortality rates according to the human development index. Asian Pac J Cancer Prev 2016;17(8):3791–94.
Sherman R, Firth R, De P, et al. Cancer In North America, 2012-2016. Vol 3. Registry-Specific Cancer Mortality in the United States and Canada. North American Association of Central Cancer Registries Inc; 2019.
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124–37.
Ilic D, Djulbegovic M, Jung J, et al.Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018;362:k3519.
Hernández J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004;101(5):894–904.
Yunusa B, Abdullahi M, Mashi SA, et al. Determination of the sensitivity and specificity of serum prostate-specific antigen in the diagnosis of prostrate cancer in Kano, Northwestern Nigeria. Niger J Basic Clin Sci 2017;14:88–91.
Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017
Laddha A, Thomas A, Nair DC, et al. Outcomes of standard 12–core transrectal ultrasound-guided prostate biopsy in biopsy naive Indian men–single center experience. Indian J Urol 2020;36(3):179–83.
Albertsen PC. Prostate cancer screening with prostate-specific antigen: Where are we going?. Cancer 2018;124(3):453–55.
Janbaziroudsari H, Mirzaei A, Maleki N. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy. Bull Cancer 2016;103(9):730–4.
Sarıkaya S, Resorlu M, Oguz U, et al. Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature. Arch Ital Urol Androl 2014;86(4):288–90.
Lotfi M, Beheshti R, Rouhezamin MR et al. A Ten–Year Study of Prostate Cancer: A Southern Iranian Experience. Iran J Med Sci 2018;43(4):372–9.
Efesoy O, Bozlu M, Çayan S, et al. Complications of transrectal ultrasound–guided 12–core prostate biopsy: a single center experience with 2049 patients. Turk J Urol 2013;39(1):6–11.
Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol 1998;160(6 Pt1):2115–20.
Stewart RW, Lizama S, Peairs K, et al. Screening for prostate cancer. Semin Oncol 2017;44(1):47–56.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
